Clinical trials: Cutaneous Melanoma, Stage II
Melanoma (Skin)
Everolimus in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098553
- Testing
- everolimus
- Where
- 94 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma (Skin)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00003222
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Unresectable Stage III Melanoma, Stage IV Melanoma
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib +…
- Trial name
- EBIN (NCT03235245)
- Testing
- Nivolumab + Ipilimumab, Encorafenib + Binimetinib
- Where
- 38 sites in Denmark, Finland and 7 more
- Volunteers
- 271 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Kidney Cancer, Melanoma (Skin)
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma…
- Trial name
- NCT00082914
- Testing
- denileukin diftitox
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Stage II Melanoma
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
This study's hypothesis is that patients with stage II melanoma who test positive for circulating tumor DNA are at a higher risk for recurrence and therefore adjuvant treatment is justified.
- Trial name
- NCT05060003
- Testing
- Atezolizumab, Tiragolumab, Signatera Assay
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Malignant Melanoma
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Currently, there is no widely used adjuvant treatment available to improve survival after surgical excision of a primary melanoma.
- Trial name
- INTRIM (NCT04126876)
- Testing
- Tilsotolimod, Saline (0.9% sodium chloride)
- Where
- Netherlands
- Volunteers
- 214 people
- Sponsor
- A.J.M. van den Eertwegh
Melanoma (Skin)
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00104897
- Testing
- tanespimycin
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Cancer Research UK
Melanoma (Skin)
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.
- Trial name
- NCT00897520
- Testing
- recombinant interferon alfa, proteomic profiling, immunoenzyme technique
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer, Melanoma (Skin)
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 3521 in treating patients who have advanced…
- Trial name
- NCT00003989
- Testing
- ISIS 3521
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients…
- Trial name
- NCT00861406
- Testing
- Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Melanoma (Skin)
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00755976
- Testing
- epirubicin hydrochloride, sulindac, immunologic technique
- Where
- 10 sites in Ireland
- Volunteers
- 32 people
- Sponsor
- Cancer Trials Ireland
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
This phase II trial studies how well stereotactic radiosurgery works in treating patients with melanoma that has spread to more than 3 places in the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT01644591
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT04990726
- Testing
- Assessment, Biospecimen Collection, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients who have undergone surgery for stage IIB, stage IIC, stage III, or stage…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma
- Trial name
- NCT00089063
- Testing
- tyrosinase peptide, gp100 antigen, MART-1 antigen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT02272855
- Testing
- HF10 plus Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takara Bio Inc.
Melanoma (Skin)
ABT-510 in Treating Patients With Metastatic Melanoma
RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients with metastatic melanoma.
- Trial name
- NCT00602199
- Testing
- ABT-510, immunoenzyme technique, immunohistochemistry staining method
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells combined with melanoma antigens may make the body build an immune response to tumor cells.
- Trial name
- NCT00004025
- Testing
- aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company